SCHEMBL8200488

SCHEMBL8200488

COc1ccccc1-c1c(-c2ccc(C3=NCCN3)cc2)nc2ccccn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 8/20 0.44
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAOB P27338 1/20 0.41
PDCD1LG2 Q9BQ51 1/20 0.40
CD274 Q9NZQ7 1/20 0.40
PTGIR P43119 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
USP7 Q93009 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8197219 0.85 NISCH (0.59) NISCHNPC1RAB9AMAOBPTGIR
SCHEMBL8218755 0.83 NISCH (0.54) NISCHMAOBALDH1A1
SCHEMBL8218711 0.82 NISCH (0.56) NISCHNPC1RAB9AMAOBALDH1A1
SCHEMBL8188045 0.82 NISCH (0.59) NISCHNPC1RAB9AMAOBPTGIR
SCHEMBL8200571 0.81 NISCH (0.56) NISCHNPC1RAB9AMAOBKDM4E
SCHEMBL8196592 0.78 NISCH (0.62) NISCHMAOBPDCD1LG2CD274PTGIR
SCHEMBL8203694 0.77 AKT1 (0.43) NISCHMAOBALDH1A1SMN1; SMN2
SCHEMBL8201080 0.76 NISCH (0.50) NISCHNPC1RAB9AMAOBKDM4E
Hydrochloric Acid SCHEMBL8200562 0.73 NISCH (0.56) NISCHMAOBKDM4EALDH1A1NR1I3
Hydrochloric Acid SCHEMBL8202383 0.71 ALDH1A3 (0.46) NISCHNPC1RAB9AMAOBPDCD1LG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000078726-A1 IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES ELI LILLY AND COMPANY (US) 2000-12-28 WO disclosed